IL254457B - A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection - Google Patents

A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection

Info

Publication number
IL254457B
IL254457B IL254457A IL25445717A IL254457B IL 254457 B IL254457 B IL 254457B IL 254457 A IL254457 A IL 254457A IL 25445717 A IL25445717 A IL 25445717A IL 254457 B IL254457 B IL 254457B
Authority
IL
Israel
Prior art keywords
agent
lysosomotropic
treatment
combination
bacterial infection
Prior art date
Application number
IL254457A
Other languages
English (en)
Hebrew (he)
Other versions
IL254457A0 (en
Inventor
Eichenseher Fritz
Original Assignee
Eichenseher Fritz
Micreos Human Health Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eichenseher Fritz, Micreos Human Health Bv filed Critical Eichenseher Fritz
Publication of IL254457A0 publication Critical patent/IL254457A0/en
Publication of IL254457B publication Critical patent/IL254457B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL254457A 2015-03-12 2017-09-12 A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection IL254457B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15158880 2015-03-12
PCT/EP2016/055076 WO2016142445A2 (en) 2015-03-12 2016-03-10 A method of treatment of a bacterial infection

Publications (2)

Publication Number Publication Date
IL254457A0 IL254457A0 (en) 2017-11-30
IL254457B true IL254457B (en) 2020-03-31

Family

ID=52648929

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254457A IL254457B (en) 2015-03-12 2017-09-12 A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection

Country Status (9)

Country Link
US (1) US11690899B2 (enExample)
EP (1) EP3268023B1 (enExample)
JP (1) JP2018509415A (enExample)
KR (1) KR102683284B1 (enExample)
CN (1) CN107580503B (enExample)
AU (1) AU2016231141B2 (enExample)
IL (1) IL254457B (enExample)
SG (1) SG11201707345VA (enExample)
WO (1) WO2016142445A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427812B2 (en) * 2016-11-18 2022-08-30 Lysando Ag Antimicrobial agents against Staphylococcus aureus
WO2019068875A1 (en) 2017-10-06 2019-04-11 Micreos Human Health B.V. TREATMENT OF A HEALTH CONDITION ASSOCIATED WITH INFECTION BY ONCOGENIC BACTERIA
EP3688011A4 (en) * 2017-10-25 2021-11-24 The Administrators Of The Tulane Educational Fund PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE
US11149068B2 (en) 2018-01-05 2021-10-19 The Administrator Of The Tulane Educational Fund Pore-forming peptides and uses thereof
JP7131803B2 (ja) * 2018-05-15 2022-09-06 学校法人大阪医科薬科大学 Gb3蓄積起因性疾患の予防又は治療剤
MX2020014006A (es) * 2018-06-29 2021-05-27 Res Inst Nationwide Childrens Hospital Composiciones y métodos para mediar la eps.
CN109350618B (zh) * 2018-12-10 2021-09-28 山东农业大学 自噬调节剂在消除牛乳腺上皮细胞内金黄色葡萄球菌中的应用
CN120136980A (zh) * 2019-05-08 2025-06-13 生物技术公司 新的加德纳菌内溶素及其用途
GB201906653D0 (en) * 2019-05-10 2019-06-26 Cc Biotech Ltd Polypeptides for treatment of bacterial infections
CA3171721A1 (en) 2020-03-19 2021-09-23 Fritz Eichenseher A stabilized protein of interest
WO2024020533A1 (en) * 2022-07-22 2024-01-25 Endolytix Technology, Inc. Immunogenic compositions for treating or preventing actinomycetia infections
AU2023408646A1 (en) * 2022-12-23 2025-07-31 Micreos Pharmaceuticals Ag A chimeric endolysin polypeptide
CN120513297A (zh) * 2023-01-09 2025-08-19 华中农业大学 细菌裂解酶及其应用
WO2024200687A1 (en) * 2023-03-29 2024-10-03 Universiteit Gent Chimeric endolysins with activity against streptococci and staphylococci
WO2024241070A1 (en) 2023-05-22 2024-11-28 L'oreal Cosmetic composition comprising an endolysin and a polyvinyl alcohol
FR3149202B1 (fr) 2023-06-02 2026-04-10 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et une huile.
FR3149209B1 (fr) 2023-06-02 2026-04-03 Oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un alcool aromatique
FR3149204B1 (fr) 2023-06-02 2026-02-13 Oreal Composition cosmétique comprenant une endolysine et un tensioactif non ionique comprenant un résidu carbohydrate
FR3149206B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique aqueuse comprenant une endolysine et du tréhalose
FR3149205B1 (fr) 2023-06-02 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et un agent de charge organique
FR3152395A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et la 4-hydroxyacetophenone
EP4719330A1 (en) 2023-06-02 2026-04-08 L'oreal Cosmetic composition comprising an endolysin derived from a staphylococcus aureus phage and an aromatic alcohol
FR3149208B1 (fr) 2023-06-02 2026-03-20 Oreal Composition cosmétique, notamment aqueuse, comprenant une endolysine et un pullulane
FR3149207B1 (fr) 2023-06-02 2026-03-13 Oreal Composition cosmétique comprenant une endolysine et un composé de formule (I)
FR3149203B1 (fr) 2023-06-02 2026-03-13 Oreal Composition anhydre comprenant une endolysine et de l’hydroxypropylmethylcellulose et/ou du pullulane
FR3152394B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine et des particules d’aérogel de silice hydrophobe
FR3152396A1 (fr) 2023-08-28 2025-03-07 L'oreal Composition cosmétique comprenant une endolysine dérivée de phage de Staphylococcus aureus et un polyhydroxyalcane
FR3152393B1 (fr) 2023-08-28 2026-04-24 Oreal Composition cosmétique comprenant une endolysine dérivée d’un phage de Staphylococcus aureus et une charge minérale
WO2025093666A1 (en) 2023-11-01 2025-05-08 University Of Copenhagen Treatment of lymphoma
WO2026052743A1 (en) 2024-09-04 2026-03-12 Micreos Human Health B.V. Reduction of trans-epidermal water loss by a polypeptide with antibacterial properties

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020187136A1 (en) * 2000-04-28 2002-12-12 Lawrence Loomis Use of bacterial phage associated lysing enzymes for treating various illnesses
US20040023897A1 (en) * 2001-11-13 2004-02-05 Caplan Michael J. Methods for preventing or treating disease mediated by toxin-secreting bacteria
KR100759988B1 (ko) * 2006-08-04 2007-09-19 주식회사 인트론바이오테크놀로지 황색포도상구균에 특이적인 항균 단백질
US20100028334A1 (en) * 2006-12-15 2010-02-04 Trustees Of Boston University Compositions and methods to potentiate colistin activity
US8383102B2 (en) 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens
SG178440A1 (en) 2009-08-24 2012-04-27 Univ Leuven Kath New endolysin obpgplys
EP2338916A1 (en) 2009-12-23 2011-06-29 Hyglos Invest GmbH Chimeric polypeptides and their use in bacterial decoloniation
US20140120074A1 (en) 2011-04-27 2014-05-01 Lysando Ag Antimicrobial agents
CN103703127A (zh) 2011-05-04 2014-04-02 迈克瑞欧斯人体健康有限公司 一种多肽
SG11201407284TA (en) 2012-05-07 2014-12-30 Micreos Human Health Bv Polypeptide mixes with antibacterial activity
KR20210121313A (ko) * 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
US9603909B2 (en) * 2012-05-29 2017-03-28 Intron Biotechnology, Inc. Composition capable of improving stability of bacteriophage lysin proteins
US9206411B2 (en) * 2012-06-13 2015-12-08 The United States Of America, As Represented By The Secretary Of Agriculture Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus
EP2679677A1 (en) 2012-06-29 2014-01-01 Lysando Aktiengesellschaft Composition for use in Mycobacteria therapy
US20160097044A1 (en) 2014-10-01 2016-04-07 The United States Of America, As Represented By The Secretary Of Agriculture Antimicrobial Enzyme Fusions Reduce Resistance and Kill Intracellular Staphylococcus aureus

Also Published As

Publication number Publication date
KR20170132201A (ko) 2017-12-01
AU2016231141B2 (en) 2022-03-03
KR102683284B1 (ko) 2024-07-10
CA2979873A1 (en) 2016-09-15
US20180271952A1 (en) 2018-09-27
CN107580503A (zh) 2018-01-12
EP3268023B1 (en) 2021-08-18
IL254457A0 (en) 2017-11-30
JP2018509415A (ja) 2018-04-05
BR112017019413A2 (pt) 2018-05-02
AU2016231141A1 (en) 2017-09-28
WO2016142445A2 (en) 2016-09-15
SG11201707345VA (en) 2017-10-30
HK1249033A1 (en) 2018-10-26
WO2016142445A3 (en) 2016-11-10
CN107580503B (zh) 2021-07-09
EP3268023A2 (en) 2018-01-17
US11690899B2 (en) 2023-07-04

Similar Documents

Publication Publication Date Title
IL254457B (en) A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection
ZA201802719B (en) Treatment compositions providing an antimicrobial benefit
ZA201703245B (en) Combination therapy for treatment of resistant bacterial infections
GB201519088D0 (en) The use of bacteria formulations
PL3497095T3 (pl) Związki chelatujące cynk do stosowania w leczeniu zakażenia bakteryjnego
GB2538923B (en) A therapeutic agent for use in the treatment of infections
PL3448992T3 (pl) Środki przeciwdrobnoustrojowe na bakterie Salmonella
IL250596A0 (en) The composition for the treatment and prevention of urinary tract infections
GB201617820D0 (en) Dental treatment
EP3236988B8 (en) Pharmaceutical compositions for the treatment of bacterial superinfections post-influenza
IL253878A0 (en) An effective substance for the treatment of respiratory inflammation
GB201805196D0 (en) Fluid treatment
EP3479785A4 (en) MEDICAL TREATMENT DEVICE
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
GB201708650D0 (en) Combination therapy for bacterial infection
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB2563431B (en) Blood treatment machine
GB201809077D0 (en) Fluid treatment
ZA201705781B (en) Pharmaceutical compositions for the treatment of bacterial infections
GB201720783D0 (en) rTMS Treatment Pathway
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201523017D0 (en) The combination of chinese medicine for treating urinary tract infection
AU2016902139A0 (en) New Therapeutic Treatment Combination
GB201409434D0 (en) Combinations useful for the treatment of bacterial infectious diseases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed